key: cord-0962094-kkykcupp
authors: Hatoum, Alexander S.; Morrison, Claire L.; Colbert, Sarah M.C.; Winiger, Evan A.; Johnson, Emma C.; Agrawal, Arpana; Bogdan, Ryan
title: Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization
date: 2021-06-19
journal: Biological psychiatry global open science
DOI: 10.1016/j.bpsgos.2021.06.005
sha: 4e1588d0c6494c59ca6b35e727d04d3bc3cd3f66
doc_id: 962094
cord_uid: kkykcupp

Background Vulnerability to COVID-19 hospitalization has been linked to behavioral risk factors, including combustible psychoactive substance use (e.g., tobacco smoking). Paralleling the COVID-19 crisis have been increasingly permissive laws for recreational cannabis use. Cannabis Use Disorder (CUD) is a psychiatric disorder that is heritable and genetically correlated with respiratory disease, independent of tobacco smoking. We examined the genetic relationship between CUD and COVID-19 hospitalization. Methods We estimated the genetic correlation between CUD (n case=14,080, n control=343,726) and COVID-19 hospitalization (n case=9,373, n control=1,197,256) using summary statistics from genome-wide association studies (GWASs). Using independent GWASs conducted prior to the pandemic, we controlled for several covariates (i.e., tobacco use phenotypes, problematic alcohol use, BMI, fasting glucose, forced expiration volume, education attainment, risk-taking, ADHD, and Townsend Deprivation Index; as well as chronic obstructive pulmonary disease, hypertension and type 2 diabetes) using genomic structural equation modeling. Genetic causality between CUD and COVID-19 hospitalization was estimated using latent causal variable models. Results Genetic vulnerability to COVID-19 was correlated with genetic liability to CUD (rG=0.423(.0965), p=1.33e-6); this association remained when accounting for genetic liability to related risk factors and covariates (b = 0.381 - 0.539, p=0.012 - 0.049). Latent causal variable analysis revealed causal effect estimates that were not statistically significant. Conclusions Problematic cannabis use and vulnerability to serious COVID-19 complications share genetic underpinnings that are unique from common correlates. While CUD may plausibly contribute to severe COVID-19 presentations, causal inference models yielded no evidence of putative causation. Curbing excessive cannabis use may mitigate COVID-19’s impact.

Paralleling the Coronavirus Disease 2019 (COVID-19) pandemic has been an increase in 65 substance use (1) and a continuation of increasingly permissive laws surrounding cannabis. On 66

February 5th, 2021, the state of Virginia voted to join 15 states (and the District of Columbia) 67

that have already legalized recreational cannabis use. Legalization is associated with increased 68 use and 20% of individuals who have tried cannabis develop cannabis use disorder (CUD) (2), a 69 moderately heritable (50-60%) psychiatric syndrome (3) that shares risk with respiratory disease 70

(4). As the heterogeneous presentation of COVID-19 is partially attributable to host genomic 71

background and respiratory symptoms are the primary reason for hospitalization and death (5), 72

CUD may contribute to severe COVID-19 presentations. 73

The COVID-19 Host Genetics Initiative represents a collaboration of international 74

investigators with data examining various aspects of COVID-19 illness via GWAS. This effort 75

includes laboratory-confirmed, physician-designated and severe COVID-19 hospitalization, with 76

comparisons to assessed and general population controls (5). Consistent with evidence that CUD 77

is associated with heightened COVID-19 risk and lifetime SUD is associated with COVID-19 78 hospitalization and death (6), phenome-wide association studies have begun to demonstrate 79 genetic associations between these COVID-19 disease definitions and a host of substance use 80 behaviors (7). Mendelian Randomization, an approach aimed at estimating causality using 81 genetic instruments (e.g., genome-wide significant variants; (8)), has also elucidated putative 82 causal effects of correlated conditions, such as body mass index (BMI), on COVID-19 (9). 83

Here, we leveraged genome-wide association study (GWAS) summary statistics to 84 estimate whether genetic liability to CUD (n case=14,080, n control=343,726; (4)) may plausibly 85

influence COVID-19 hospitalization (n=9,373, n control=1,197,256) (5)). First, we estimate their 86 genetic correlation using Linkage Disequilibrium Score Regression (10). Then, we use Genomic 87

Structural Equation Modeling (gSEM) (11) to test whether the genetic correlation between CUD 88

and COVID-19 is independent of potential confounders (i.e., tobacco-smoking phenotypes, 89

problematic alcohol use, cannabis use, pulmonary function, metabolic, socioeconomic status, and 90

impulsivity; as well as chronic conditions, such as Chronic Obstructive Pulmonary Disease, 91

Hypertension and Type2 Diabetes in supplemental analyses). Finally, we employ Latent Causal 92

Variable (LCV) (12) analyses to test for putative causal relationships between CUD and COVID-93 19 hospitalization. We hypothesized that genetic liability to CUD would be correlated with 94 COVID-19 hospitalization and that we would find evidence of potential causal influence (i.e., 95 association that is independent of confounders and evidence of putative causation in genetic 96 causal modeling analyses). 97 J o u r n a l P r e -p r o o f traits based on GWAS summary statistics (i.e., effect sizes). Both traits do not need to be 213 assessed in the same individuals or even the same GWAS. LDSC also separates any potential 214 sample overlap or other sources of confounding (e.g., population stratification) from SNP 215 heritability (i.e., when examining one trait) and SNP-genetic correlation (SNP-rG; i.e., when 216 examining a pair of traits) estimates. 217

We first applied standard filters to the summary statistics of each trait (only SNPs with 218 MAF >.01 and INFO scores > .9). Palindromic and multi-allelic SNPs and insertion/deletion 219 polymorphisms were excluded before estimating genetic correlations. SNPs with less than 1000 220 individuals were removed (this was partially done to remove SNPs specific to any minority 221 ancestral populations). All summary statistics were aligned with reference genome data from the 222

Haplotype Reference Consortium (23) and normalized to a standard Z statistic, which placed all 223 summary statistics on the same scale for analyses. LDSC beta weights and LD scores were pre-224 generated from 1000 Genomes Phase 3 European GWAS data included in the LDSC software 225

download. LD score regression estimates were subsequently also used for gSEM analyses and 226

the LD score regression 4 th order moments were used as inputs for LCV analyses. 227

One advantage of LDSC is the ability to account for spurious sample overlap in GWAS 228

contributing to the genetic correlation. Sample overlap can induce population stratification (e.g., 229

overlapping controls may be more related to each other), and when unaccounted for, can 230

upwardly bias the genetic correlation estimate. However, LDSC parses overlap from genetic 231 correlation into the model intercept (i.e., intercept not at origin), while the slope, which is used to 232

calculate the bivariate SNP-rG, remains unbiased. Assuming the intercept is not constrained at 233 0, this allows the model to remain robust to sample overlap when estimating the rG (10). This 234 remains true even when the heritability estimates themselves are poorly estimated (24 genomic risk for a given phenotype, in our case CUD, as proxy measures for assignment to 262 elevated exposure on these phenotypes, at the group level (for additional information please see 263 (25)). As such, these models theoretically test whether one phenotype may plausibly cause 264

another. Here, our genomic causal inference models stipulate that individuals are randomly 265 assigned to polygenic liability to CUD, which can be interpreted to reflect a group level 266 likelihood of CUD expression (which would include noise from those with high genomic 267 J o u r n a l P r e -p r o o f COVID-19 hospitalization) using 4 th order moments from LDSC. Furthermore, LCV includes 272 genetic variants across the entire genome as "instruments", unlike traditional MR methods that 273 select the most strongly associated variants (typically with p < 5e-8). 274

The LCV model is premised on estimating a latent variable "L" that represents the 275 consistency of effects of trait 1 on trait 2; i.e., if there are causal effects of trait 1 (CUD) on trait 276 2 (COVID-19 hospitalization), genetic associations with trait 1 (CUD) would correlate with the 277 latent causal variable (L). The extent to which the latent causal variable "L" causes CUD (q CUD ) 278

versus COVID-19 (q COVID ) is expressed as a ratio between 0 and 1 (i.e. .3 for 30 percent). This 279 ratio is further distilled from the genetic correlation between CUD and COVID-19 (ρ g ) to obtain 280 the extent to which CUD and COVID-19 might be causally related. As q CUD and q COVID are 281 simultaneously estimated, no additional multiple testing is required to account for reciprocal 282 effects of "outcome" on "exposure". The extent to which the latent "causal" variable mediates 283 the genetic correlation between the two traits is quantified by the Genetic Causality Proportion 284

(GCP), an estimate of the degree to which each trait is correlated with the latent genetic variable 285

(ranging from 0 reflecting no genetic causality to |1| indicating full genetic causality). For 286 example, a GCP of 0.50 suggests that 50% of SNP effect sizes are consistent with trait A (i.e., 287 CUD) causing trait B (i.e., COVID-19 hospitalization); however, potential residual mechanisms 288

(pleiotropy and error) may remain. 289

Genetic correlations: CUD and COVID-19 hospitalization were genetically correlated, even 292

after Bonferroni correction for all traits examined (SNP-rG=0.418 (SE=0.097), p= 1.34 e-06 ; Fig.  293 1). COVID-19 hospitalization was also genetically correlated with other variables, most notably 294 BMI, smoking cessation and educational attainment (rG > 0.3). As has been previously 295 demonstrated (4), CUD was most highly correlated with cannabis use (rG=.48 (SE=0.042)) and 296

other substance use measures (rG > .31-.48).

Genetic association accounting for other factors: Despite genetic correlations between 299

COVID-19 hospitalization and other related phenotypes (e.g., tobacco use phenotypes, BMI; Fig.  300 1), a series of gSEM models revealed an independent association between CUD and COVID-19 301 hospitalization ( when adjusting for cannabis use or smoking cessation) remained genetically correlated with 312 genetic vulnerability to COVID-19 hospitalization in the multivariable models (Table 1) .

In secondary sensitivity analyses, we examined whether including GWAS of chronic diagnosable 315 health conditions, including COPD (rather than FEV), and Type 2 Diabetes (rather than fasting 316 glucose) as well as Hypertension as putative genetic covariates influenced our findings. While 317 the GWAS of these disorder states represents greater severity and potential COVID-19 risk, they 318

do not capture the range of variability in the underlying predisposing symptoms (i.e., respiration 319 and metabolic dysregulation). Indeed, the genetic correlation between FEV and COPD was 0.190 320 (SE=.020), fasting glucose was genetically correlated with Type 2 Diabetes (rG=0.564 321 (SE=0.055)) and Hypertension (rG=0.256 (SE=.055)). CUD was genetically correlated with 322

Type 2 Diabetes (rG=0.149 (SE=0.041)) and HTN (rG=0.223, (SE=0.070)) and weakly with 323 COPD (rG=0.098, (SE=0.037)). Likewise, COVID-19 hospitalization was genetically correlated 324

with Type 2 Diabetes (rG=0.363 (SE=0.060)) and HTN (rG=0.419, (SE=0.140)) and with COPD 325 (rG=0.231, (SE=0.050)). When FEV and fasting glucose were replaced by COPD, Type 2 326

Diabetes and Hypertension, results remained largely unchanged and CUD remained genetically 327 correlated with COVID-19 hospitalization, except when controlling for marijuana use, in which 328

CUD was reduced to marginally significant but effect sizes were similar (Table S2 ; 329

Supplemental Figure 1 for full genetic correlation matrix). 330 331 a As the Townsend Deprivation Index is a geographic index from the UK Biobank that may reflect a multitude of factors (e.g., migration), we repeated analyses excluding this as a covariate. As depicted in Table S1 , conclusions are not altered by doing so.

Genetic causality: LCV analyses did not provide significant evidence that liability to CUD may 332 be genetically causal for COVID-19 hospitalization. Even though the effect size of the genetic 333 causality proportion was substantial, it was not statistically significant (genetic causality 334

proportion estimate = 0.38, SE = 0.36, p=0.58); that is, after accounting for pleiotropy between 335 CUD and COVID-19, there was no statistically significant evidence of a potentially causal effect 336

of genetic liability to CUD on COVID-19 hospitalization risk. 337 J o u r n a l P r e -p r o o f Hatoum 11

Our findings suggest that genetic liability to CUD is correlated with risk for COVID-19 340

hospitalization. The genetic correlation between CUD and COVID-19 hospitalization was 341 independent of potential confounding variables (e.g., other substance inhalation phenotypes, 342

cardio-metabolic traits, respiration, socioeconomic status indicators). On the other hand, genetic 343 liability to lifetime cannabis ever-use showed a non-significant, but negative, genetic correlation 344

with COVID-19 hospitalization (Figure 1; Table 1) ; divergent associations of cannabis use and 345 CUD in their genetic association has been observed for other phenotypes (e.g., BMI, which is 346 also positively genetically correlated with CUD and negatively with cannabis use) (4). Further, 347

when genomic liability to lifetime cannabis use was included in models, the association between 348

CUD and COVID-19 hospitalization became stronger (Figure 1 ; J o u r n a l P r e -p r o o f Note. Standardized beta estimates for Cannabis Use Disorder (CUD) and substance use phenotypes were taken from a multiple regression parameterized in gSEM. # Substance use phenotypes were entered and tested separately to avoid multicollinearity amongst them. Each row represents genetic correlations with COVID-19 hospitalization from one model. The multiple rows indicate the separate models run substituting each substance use phenotype (listed in the first column). The model was COVID hospitalization = CUD + substance use phenotype + BMI + Townsend Deprivation index + Educational Attainment + Forced Expiration + Fasting Glucose + ADHD + Risk-taking + error. The original GWAS accounted for standard GWAS covariates (age, sex, genetic principal components, etc). Bold* represents p < .05. CUD = Cannabis Use Disorder, Cannabis Use = any lifetime cannabis use, CPD = Cigarettes per day, Age Smoke = Age of smoking initiation, Ever Smoke = Ever smoking tobacco, EA = educational attainment, TDI = Townsend deprivation index, BMI = body mass index, FEV = 1 second forced expiration volume, Fast Gluc = fasting glucose, ADHD = attention deficit hyperactivity disorder, Risk = Risk-taking. When all of the above covariates were included in the model simultaneously with PAU and CUD, the partial rG between CUD and COVID-19 was no longer significant (= .315, p = 0.08). This was largely due to the number of covariates; when only PAU was included in the model, the partial r effect size for CUD was similar in magnitude and significant (r =.364, p=.004).

analysis of genome-wide association studies for height and body mass index in ~700 000 452 individuals of European ancestry

A 454 genome-wide approach accounting for body mass index identifies genetic variants 455 influencing fasting glycemic traits and insulin resistance

Genome-wide 457 association analyses identify 143 risk variants and putative regulatory mechanisms for type 458 2 diabetes

Caitlin Carey TH team

Gene discovery 463 and polygenic prediction from a genome-wide association study of educational attainment 464 in 1.1 million individuals

Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million 467 individuals identify hundreds of loci and shared genetic influences

470 Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity 471 disorder

A reference panel of 64,976 haplotypes for genotype imputation

An 476 atlas of genetic correlations across human diseases and traits

Mendelian randomization studies: A 478 review of the approaches used and the quality of reporting

An introduction to the endogenous cannabinoid system. 481 Biological Psychiatry

Search of 483 Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts

Modulate ACE2 Expression in COVID-19 Gateway Tissues

Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization

A genetically-informed study disentangling the 490 relationships between tobacco smoking, cannabis use, alcohol consumption, substance use 491 disorders and respiratory infections

ASH receives support from DA007261-17. CLM receives support from MH016880. EAW 396 receives support from HD007289-30. ECJ receives support from F32AA027435. AA receives 397 support from MH109532 and K02DA032573; RB receives support from (AG052564, 398 AA027827, DA046224). We also would like to acknowledge the COVID-19 Host Genetics 399Initiative for access to summary statistics (https://www.covid19hg.org/acknowledgements/). 400Links to publicly available GWAS summary data used in analyses are provided in the methods.

Disclosures: All authors report no biomedical financial interests or potential conflicts of interest. 403 404 J o u r n a l P r e -p r o o f